InterCure Ltd. (INCR)
USD 1.38
(-5.37%)
USD 1.38
(-5.37%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 106.29 Million ILS | -15.97% |
| 2022 | 126.49 Million ILS | 86.36% |
| 2021 | 67.87 Million ILS | 205.73% |
| 2020 | 22.2 Million ILS | 283.45% |
| 2019 | 5.79 Million ILS | 475.49% |
| 2018 | -1.54 Million ILS | -331141978521600100.0% |
| 2017 | - ILS | 100.0% |
| 2016 | -26.94 Thousand ILS | -2694200.0% |
| 2015 | 1.00 ILS | -100.0% |
| 2014 | 459.48 Thousand ILS | -56.31% |
| 2013 | 1.05 Million ILS | 22.93% |
| 2012 | 855.53 Thousand ILS | 191.93% |
| 2011 | 293.06 Thousand ILS | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 126.46 Million ILS | 0.0% |
| 2024 Q1 | 126.46 Million ILS | 19.91% |
| 2023 Q3 | 105.46 Million ILS | -26.5% |
| 2023 Q2 | 143.5 Million ILS | 5.17% |
| 2023 FY | 106.29 Million ILS | -15.97% |
| 2023 Q1 | 136.44 Million USD | 7.86% |
| 2023 Q4 | 105.46 Million ILS | 0.0% |
| 2022 Q3 | 135.29 Million ILS | 49.0% |
| 2022 Q4 | 126.49 Million ILS | -6.5% |
| 2022 Q1 | 93.34 Million ILS | 37.52% |
| 2022 Q2 | 90.79 Million ILS | -2.73% |
| 2022 FY | 126.49 Million ILS | 86.36% |
| 2021 Q3 | 51.71 Million ILS | 19.54% |
| 2021 Q4 | 67.87 Million ILS | 31.27% |
| 2021 Q1 | 20.58 Million ILS | -7.29% |
| 2021 FY | 67.87 Million ILS | 205.73% |
| 2021 Q2 | 43.25 Million ILS | 110.16% |
| 2020 FY | 22.2 Million ILS | 283.45% |
| 2020 Q2 | 11.42 Million ILS | 44.78% |
| 2020 Q3 | 15.93 Million ILS | 39.43% |
| 2020 Q4 | 22.2 Million ILS | 39.33% |
| 2020 Q1 | 7.89 Million ILS | 36.34% |
| 2019 FY | 5.79 Million ILS | 475.49% |
| 2019 Q3 | 1.44 Million ILS | -68.32% |
| 2019 Q4 | 5.79 Million ILS | 300.0% |
| 2019 Q1 | 1.44 Million ILS | 193.87% |
| 2019 Q2 | 4.56 Million ILS | 215.65% |
| 2018 Q2 | -1.91 Million ILS | -54.34% |
| 2018 Q3 | -570 Thousand ILS | 70.2% |
| 2018 Q4 | -1.54 Million ILS | -170.53% |
| 2018 FY | -1.54 Million ILS | -331141978521600100.0% |
| 2018 Q1 | -1.23 Million ILS | -229.66% |
| 2017 Q1 | -9556.90 ILS | 64.56% |
| 2017 Q3 | -345.55 Thousand ILS | -725.53% |
| 2017 Q4 | -375.99 Thousand ILS | -8.81% |
| 2017 FY | - ILS | 100.0% |
| 2017 Q2 | -41.85 Thousand ILS | -338.0% |
| 2016 Q3 | -59.98 Thousand ILS | 2.83% |
| 2016 FY | -26.94 Thousand ILS | -2694200.0% |
| 2016 Q4 | -26.96 Thousand ILS | 55.04% |
| 2016 Q2 | -61.72 Thousand ILS | -720.21% |
| 2016 Q1 | -7525.80 ILS | -752680.0% |
| 2015 Q4 | 1.00 ILS | -100.0% |
| 2015 Q3 | 106.08 Thousand ILS | -34.73% |
| 2015 Q1 | 304.67 Thousand ILS | -33.69% |
| 2015 FY | 1.00 ILS | -100.0% |
| 2015 Q2 | 162.52 Thousand ILS | -46.66% |
| 2014 Q4 | 459.48 Thousand ILS | -43.84% |
| 2014 Q3 | 818.19 Thousand ILS | -20.81% |
| 2014 Q2 | 1.03 Million ILS | 41.86% |
| 2014 Q1 | 728.36 Thousand ILS | -30.74% |
| 2014 FY | 459.48 Thousand ILS | -56.31% |
| 2013 Q4 | 1.05 Million ILS | -27.93% |
| 2013 FY | 1.05 Million ILS | 22.93% |
| 2013 Q1 | 1.18 Million ILS | 37.94% |
| 2013 Q2 | 966.73 Thousand ILS | -18.08% |
| 2013 Q3 | 1.45 Million ILS | 50.95% |
| 2012 FY | 855.53 Thousand ILS | 191.93% |
| 2012 Q2 | 213.88 Thousand ILS | 0.0% |
| 2012 Q3 | 493.88 Thousand ILS | 130.91% |
| 2012 Q4 | 855.53 Thousand ILS | 73.23% |
| 2012 Q1 | 213.88 Thousand ILS | 191.93% |
| 2011 Q1 | 73.26 Thousand ILS | 0.0% |
| 2011 FY | 293.06 Thousand ILS | 0.0% |
| 2011 Q2 | 73.26 Thousand ILS | 0.0% |
| 2011 Q3 | 73.26 Thousand ILS | 0.0% |
| 2011 Q4 | 73.26 Thousand ILS | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | 11.64 Million USD | -812.604% |
| PainReform Ltd. | - USD | -Infinity% |
| Alvotech | 74.43 Million USD | -42.801% |
| Collegium Pharmaceutical, Inc. | 32.33 Million USD | -228.749% |
| ANI Pharmaceuticals, Inc. | 111.19 Million USD | 4.411% |
| Aquestive Therapeutics, Inc. | 6.76 Million USD | -1470.261% |
| Journey Medical Corporation | 10.2 Million USD | -941.456% |
| Dynavax Technologies Corporation | 53.29 Million USD | -99.458% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | -61.972% |
| Bright Green Corporation | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 104.35 Million USD | -1.857% |
| Embecta Corp. | 152.1 Million USD | 30.118% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | -1753.453% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | -1753.453% |
| SCYNEXIS, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 1.61 Million USD | -6500.323% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| China SXT Pharmaceuticals, Inc. | 809.75 Thousand USD | -13026.284% |
| Alpha Teknova, Inc. | 11.59 Million USD | -816.776% |
| Safety Shot Inc | 1.86 Million USD | -5585.084% |
| Procaps Group, S.A. | 96.83 Million USD | -9.767% |
| Cosmos Health Inc. | 4.78 Million USD | -2119.457% |
| Theratechnologies Inc. | 6.06 Million USD | -1652.242% |
| Harrow Health, Inc. | 10.86 Million USD | -878.108% |
| Sonoma Pharmaceuticals, Inc. | 2.71 Million USD | -3809.195% |
| Biofrontera Inc. | 10.9 Million USD | -874.432% |
| DURECT Corporation | 2.21 Million USD | -4690.041% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | -37.313% |
| Cronos Group Inc. | 30.33 Million USD | -250.345% |
| OptiNose, Inc. | 8.05 Million USD | -1220.057% |
| Ironwood Pharmaceuticals, Inc. | 1.00 USD | -10629099900.0% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 5.69 Million USD | -1765.071% |
| Organogenesis Holdings Inc. | 28.25 Million USD | -276.211% |
| Guardion Health Sciences, Inc. | 2.67 Million USD | -3870.361% |
| Cumberland Pharmaceuticals Inc. | 4.6 Million USD | -2205.981% |
| Radius Health, Inc. | 278.64 Million USD | 61.854% |
| Universe Pharmaceuticals INC | 3.34 Million USD | -3079.256% |
| ProPhase Labs, Inc. | 3.84 Million USD | -2667.274% |
| Phibro Animal Health Corporation | 265.91 Million USD | 60.028% |
| Procaps Group S.A. | 96.83 Million USD | -9.767% |
| TherapeuticsMD, Inc. | - USD | -Infinity% |
| Viatris Inc. | 3.46 Billion USD | 96.937% |
| Rockwell Medical, Inc. | 5.87 Million USD | -1710.441% |
| Aytu BioPharma, Inc. | 12.63 Million USD | -741.376% |
| SIGA Technologies, Inc. | 64.21 Million USD | -65.515% |
| Tilray Brands, Inc. | 252.08 Million USD | 57.836% |
| Lifecore Biomedical, Inc. | 39.97 Million USD | -165.867% |
| Shineco, Inc. | 1.58 Million USD | -6591.176% |
| PetIQ, Inc. | 159.3 Million USD | 33.28% |
| Regencell Bioscience Holdings Limited | -152.77 Thousand USD | 69672.19% |
| Incannex Healthcare Limited | -10.01 Million USD | 1161.318% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | -177.522% |
| Alimera Sciences, Inc. | 1.87 Million USD | -5556.786% |
| Assertio Holdings, Inc. | 37.68 Million USD | -182.044% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Clever Leaves Holdings Inc. | 4.48 Million USD | -2270.979% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -41688.938% |
| Avadel Pharmaceuticals plc | 10.38 Million USD | -923.998% |
| Hempacco Co., Inc. | 2.54 Million USD | -4080.36% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 74.43 Million USD | -42.801% |
| Eagle Pharmaceuticals, Inc. | 47.79 Million USD | -122.394% |
| Lantheus Holdings, Inc. | 64.02 Million USD | -66.004% |
| Currenc Group, Inc. | 732.91 Thousand USD | -14402.579% |
| Kamada Ltd. | 87.74 Million USD | -21.134% |
| Indivior PLC | 141.79 Million USD | 25.041% |
| Evoke Pharma, Inc. | 481.84 Thousand USD | -21959.397% |
| Flora Growth Corp. | 8.5 Million USD | -1149.307% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -41688.938% |
| Evolus, Inc. | 10.99 Million USD | -866.458% |
| HUTCHMED (China) Limited | 50.25 Million USD | -111.491% |
| Amphastar Pharmaceuticals, Inc. | 105.83 Million USD | -0.433% |
| Akanda Corp. | 1.28 Million USD | -8159.499% |